ChiCTR2300067390 版本V1.0 版本创建时间2023/01/06 10:07:56 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2300067390 

最近更新日期:

Date of Last Refreshed on:

2023-01-06 10:07:36 

注册时间:

Date of Registration:

2023-01-06 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

环泊酚复合瑞芬太尼在超高龄骨科手术患者中的有效性和安全性:一项前瞻性、随机、双盲、非劣效性试验

Public title:

Efficacy and safety of cycpofol combined with remifentanil in super-elderly patients undergoing orthopedic surgery: a prospective, randomized, double-blind, non-inferiority trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

麻醉学

Scientific title:

Anesthesiology

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

吴昱 

研究负责人:

吴昱 

Applicant:

Wu Yu 

Study leader:

Wu Yu 

申请注册联系人电话:

Applicant telephone:

18633487638

研究负责人电话:

Study leader's
telephone:

18633487638

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

vwuyuv@163.com

研究负责人电子邮件:

Study leader's E-mail:

vwuyuv@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

河北省石家庄市中山西路398号

研究负责人通讯地址:

河北省石家庄市中山西路398号

Applicant address:

No. 398 Zhongshan west road, Shijiazhuang, Hebei province

Study leader's address:

No. 398 Zhongshan west road, Shijiazhuang, Hebei province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

联勤保障部队第九八〇医院

Applicant's institution:

The 980th Hospital Of Joint Logistics support Force

研究负责人所在单位:

联勤保障部队第九八〇医院

Affiliation of the Leader:

The 980th Hospital Of Joint Logistics support Force

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2023-KY-02

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

联勤保障部队第九八〇医院伦理委员会

Name of the ethic committee:

The 980th Hospital Ethics Committee of the Joint Logistic Support Force

伦理委员会批准日期:

Date of approved by ethic committee:

2023-01-03 00:00:00

伦理委员会联系人:

程琰

Contact Name of the ethic committee:

Cheng Yan

伦理委员会联系地址:

河北省石家庄市中山西路398号

Contact Address of the ethic committee:

No. 398 Zhongshan west road, Shijiazhuang, Hebei Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

联勤保障部队第九八〇医院

Primary sponsor:

The 980th Hospital Of Joint Logistics support Force

研究实施负责(组长)单位地址:

河北省石家庄市中山西路398号

Primary sponsor's address:

No. 398 Zhongshan west road, Shijiazhuang, Hebei province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

河北

市(区县):

石家庄

Country:

China

Province:

Hebei

City:

Shijiazhuang

单位(医院):

联勤保障部队第九八〇医院

具体地址:

中山西路398号

Institution
hospital:

The 980th Hospital Of Joint Logistics Support Force

Address:

398 Zhongshan West Road

经费或物资来源:

自筹

Source(s) of funding:

Self-funding

研究疾病:

围术期相关疾病  

Target disease:

Perioperative related diseases

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

上市后药物 

Study phase:

4

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本研究拟观察环泊酚对全身麻醉的超高龄骨科患者的有效性和安全性,为老年患者的围术期安全保驾护航。  

Objectives of Study:

The purpose of this study was to observe the efficacy and safety of cycpofol in ultra-elderly orthopedic patients under general anesthesia.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

行全身麻醉的患者,ASA分级I-III级,年龄>80 岁,BMI<30kg/m2,肝肾功能正常。

Inclusion criteria

The patients who underwent general anesthesia, ASA grade I-III, age > 80 years old, BMI < 30kg/m2, liver and kidney function were normal.

排除标准:

(1)长期接受支气管扩张、激素治疗者;(2)长期服用镇静、镇痛、抗精神疾病等药物者; (3)合并肾上腺皮质功能低下或不全者; (4)合并重症糖尿病、高血压、肾功能不全者;(5)麻醉药物过敏史、禁忌证者;(6)存在认知功能障碍者;(7)家属或者患者本人拒绝。

Exclusion criteria:

(1) long-term recipients of bronchiectasis and hormone therapy; (2) long-term use of sedative, analgesic, antipsychotic drugs; (3) Patients with adrenocortical hypofunction or insufficiency; (4) Patients with severe diabetes, hypertension and renal insufficiency; (5) Allergic history of narcotic drugs, contraindicated evidence; (6) People with cognitive dysfunction; (7) Family members or patients themselves refuse.

研究实施时间:

Study execute time:

From 2023-01-16 00:00:00 To 2023-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-01-16 00:00:00 To 2023-12-31 00:00:00

干预措施:

Interventions:

组别:

1组

样本量:

40

Group:

Group 1

Sample size:

干预措施:

环泊酚

干预措施代码:

Intervention:

Cycpofol

Intervention code:

组别:

2组

样本量:

40

Group:

Group 2

Sample size:

干预措施:

丙泊酚

干预措施代码:

Intervention:

Propofol

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

河北 

市(区县):

 

Country:

China

Province:

Hebei

City:

单位(医院):

联勤保障部队第九八〇医院 

单位级别:

三甲 

Institution
hospital:

The 980th Hospital Of Joint Logistics Support Force

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

全麻诱导成功率

指标类型:

主要指标

Outcome:

success rate of induction in general anesthesia

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

收缩压的最大下降幅度

指标类型:

次要指标

Outcome:

The maximum decrease in systolic blood pressure

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

全麻诱导成功时间

指标类型:

次要指标

Outcome:

time of successful induction of general anesthesia

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

BIS最低值

指标类型:

次要指标

Outcome:

The lowest BIS

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心率

指标类型:

次要指标

Outcome:

Heart Rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血压

指标类型:

次要指标

Outcome:

blood presure

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

动脉血气分析

指标类型:

次要指标

Outcome:

Arterial blood gas analysis

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后认知功能评估

指标类型:

主要指标

Outcome:

Postoperative cognitive function evaluation

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 80 years
最大 Max age 100 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

一位没有参与试验的麻醉医师使用密封的信封进行随机分组

Randomization Procedure (please state who generates the random number sequence and by what method):

An anesthesiologist who did not participate in the trial was randomized into groups using sealed envelopes

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

暂不共享原始数据

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

No data sharing will be provided

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case record table

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2023-01-06 10:07:37